Gefitinib in lung cancer therapy: Clinical results, predictive markers of response and future perspectives

Authors:
  • TFTindara Franchina
    Tindara Franchina
  • BABarbara Adamo
    Barbara Adamo
  • NDNerina Denaro
    Nerina Denaro
  • PGPietro Gambadauro
    Pietro Gambadauro
  • GCGiuseppe Chiofalo
    Giuseppe Chiofalo
  • ASAntonio Scimone
    Antonio Scimone
  • NCNicola Caristi
    Nicola Caristi
  • ARAntonio Russo
    Antonio Russo
Open Access
Publisher website
Google Scholar
Abstract
Over the past few years, epidermal growth factor receptor has emerged as one of the most important targets in tumorgenesis and several drugs targeting signal transduction pathways have been developed. The first among these agents to be approved for the treatment of NSCLC was gefitinib, a potent, selective and reversible inhibitor of HER1/EGFR tyrosine kinase activity. The review summarizes its clinical development and the new therapeutic options, with particular focus on predictive markers of susceptibility to this drug.